ViroVet
PrivateLast Round
Series C
Jun 16, 2022
Total Funding Raised
$24.05M
Company Overview
ViroVet operates in Healthcare & Life Sciences and is based in Leuven. Its latest recorded funding round was a Series C round in June 2022.
ViroVet is a biotechnology company that develops innovative technologies, including antiviral drugs and vaccines, for the control of viral diseases in livestock.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ViroVet Comparables
Compare ViroVet with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| VEROVACCiNES GmbH | 81% | |
| The Vaccine Group | 80% | |
| Genvax Technologies | 78% |
For institutional investors. Book with your work email.
ViroVet Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 16, 2022 | ||||
| Series B | May 28, 2020 | ||||
| Grant | Sep 1, 2018 | ||||
| Series A Extension | Oct 4, 2017 | ||||
| Series A | Jan 10, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ViroVet Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Capricorn Partners | Series B, Series C, Series A, Series A Extension |
| Gimv | Series B, Series C |
| KU Leuven Research & Development (LRD) | Series B, Series C |
| KU Leuven | Series B, Series A |
| VIVES II - Louvain Technology Fund | Series B, Series A |
| VLAIO | Grant |
| VIVES Partners | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 16, 2022
Raised $8M from Gimv, Capricorn Partners, and others.
- May 28, 2020
$7M round led by Seventure Partners
For institutional investors. Book with your work email.
ViroVet Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ViroVet's valuation, stock price, and market status.
Is ViroVet a public or private company?
ViroVet is a private company.
What is the current stock price of ViroVet?
ViroVet is a private company, so its shares have no public market price. Caplight tracks ViroVet's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ViroVet worth (valuation)?
Valuation information for ViroVet is not publicly available.
Can I buy ViroVet stock?
ViroVet shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ViroVet's last funding round?
ViroVet's most recent funding round was Series C on June 16, 2022.
Who are the main investors in ViroVet?
Key investors in ViroVet include Capricorn Partners, PMV, Maatschappij voor Roerend Bezit van de Boerenbond, Seventure Partners.
Will ViroVet IPO soon?
No public IPO plans have been announced for ViroVet.
How can I track ViroVet secondary market activity?
Caplight tracks bids, offers, and trades in ViroVet's shares on secondary markets.